StrokeDx, a leader in next-generation stroke technology, has closed an oversubscribed $5 million Series Seed Prime funding round.
Led by DigiTx Partners, with participation from Freeflow Ventures and other investors experienced in neuroradiology, stroke, and medical devices. This brings StrokeDx’s total funding to nearly $10 million, including an NIH R01 Grant. David J. Kim, MD, Managing Director of DigiTx Partners, will join the board. The funds will support further clinical validation and commercial expansion of StrokeDx’s innovative technology.
Do you need investors for your startup?
StrokeDx develops advanced, portable, non-invasive, and non-radiating cerebrovascular monitoring technology. Founded by Shane Shahrestani, MD, PhD, at Caltech, this technology provides a precise method for stroke surveillance. The societal impact of StrokeDx’s technology is significant, offering a scalable solution to improve stroke outcomes and address healthcare accessibility and equity issues.
Stroke is a leading cause of death and disability worldwide, making early detection and rapid monitoring crucial for improving survival rates and quality of life. StrokeDx’s portable devices enable point-of-care monitoring, allowing for early intervention.
To read full article / source click here
* It is a community posted article. Please read the Full Disclaimer below
Disclaimer: This post is AI-generated. Its content does not represent the views of Xstartups. Xstartups is not liable for the accuracy or implications of the content. For any concerns or copyright issue, contact us at complaint@xstartups.co.
